266 related articles for article (PubMed ID: 16627989)
1. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
[TBL] [Abstract][Full Text] [Related]
2. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
[TBL] [Abstract][Full Text] [Related]
3. ADAM10 and ADAM17: New players in trastuzumab tesistance.
Duffy MJ; Crown J; Mullooly M
Oncotarget; 2014 Nov; 5(22):10963-4. PubMed ID: 25460503
[No Abstract] [Full Text] [Related]
4. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding.
Wojtalewicz N; Sadeqzadeh E; Weiß JV; Tehrani MM; Klein-Scory S; Hahn S; Schmiegel W; Warnken U; Schnölzer M; de Bock CE; Thorne RF; Schwarte-Waldhoff I
PLoS One; 2014; 9(3):e90461. PubMed ID: 24625754
[TBL] [Abstract][Full Text] [Related]
5. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
6. Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10.
Prox J; Willenbrock M; Weber S; Lehmann T; Schmidt-Arras D; Schwanbeck R; Saftig P; Schwake M
Cell Mol Life Sci; 2012 Sep; 69(17):2919-32. PubMed ID: 22446748
[TBL] [Abstract][Full Text] [Related]
7. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
Zheng H; Zhong A; Xie S; Wang Y; Sun J; Zhang J; Tong Y; Chen M; Zhang G; Ma Q; Kai J; Guo L; Lu R
Cancer Med; 2019 Feb; 8(2):679-685. PubMed ID: 30661303
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
[TBL] [Abstract][Full Text] [Related]
10. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
11. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
Grabowska MM; Sandhu B; Day ML
Cell Signal; 2012 Feb; 24(2):532-538. PubMed ID: 22024284
[TBL] [Abstract][Full Text] [Related]
12. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A.
Herzog C; Haun RS; Ludwig A; Shah SV; Kaushal GP
J Biol Chem; 2014 May; 289(19):13308-22. PubMed ID: 24662289
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
Yang M; Li Y; Kong L; Huang S; He L; Liu P; Mo S; Lu X; Lin X; Xiao Y; Shi D; Huang X; Chen B; Chen X; Ouyang Y; Li J; Lin C; Song L
J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37463446
[TBL] [Abstract][Full Text] [Related]
15. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.
Ergün S; Ulasli M; Igci YZ; Igci M; Kırkbes S; Borazan E; Balik A; Yumrutaş Ö; Camci C; Cakmak EA; Arslan A; Oztuzcu S
Mol Biol Rep; 2015 Feb; 42(2):497-505. PubMed ID: 25318895
[TBL] [Abstract][Full Text] [Related]
16. ADAM10: a new player in breast cancer progression?
Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
Tsang JYS; Lee MA; Chan TH; Li J; Ni YB; Shao Y; Chan SK; Cheungc SY; Lau KF; Tse GMK
EBioMedicine; 2018 Dec; 38():89-99. PubMed ID: 30470613
[TBL] [Abstract][Full Text] [Related]
18. T-cell immunoglobulin and mucin domain 2 (TIM-2) is a target of ADAM10-mediated ectodomain shedding.
Dewitz C; Möller-Hackbarth K; Schweigert O; Reiss K; Chalaris A; Scheller J; Rose-John S
FEBS J; 2014 Jan; 281(1):157-74. PubMed ID: 24164679
[TBL] [Abstract][Full Text] [Related]
19. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
20. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
Ebbing EA; Medema JP; Damhofer H; Meijer SL; Krishnadath KK; van Berge Henegouwen MI; Bijlsma MF; van Laarhoven HW
Oncotarget; 2016 Mar; 7(9):10243-54. PubMed ID: 26863569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]